Related Experiment Video
Updated: Jun 18, 2026
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
Published on: November 2, 2013
Screening for Prostate Cancer: A Review of the ERSPC and PLCO Trials
Elisabeth Eckersberger1, Julia Finkelstein, Helen Sadri
1Department of Urology, School of Medicine, New York University New York, NY.
Abstract:
The advent of prostate-specific antigen (PSA) testing in the early 1980s revolutionized the diagnosis of prostate cancer. As a result of PSA testing, there has been a surge in the number of prostate cancer diagnoses. This review examines the results of 2 recent landmark trials that studied the effect of screening on prostate cancer mortality: the European Randomized Study of Screening for Prostate Cancer (ERSPC) and the US-based Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
